Skip to content
Menu
Press Releases
Filter Releases
 
EMERYVILLE, Calif., April 30, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today presented data on the safety and efficacy of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a serious movement disorder associated with Parkinson's disease treatment. The data, from Adamas' Phas...
Apr 30, 2014 General Releases HTML PDF
EMERYVILLE, Calif., April 23, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today announced a poster presentation at the American Academy of Neurology (AAN) 66th Annual Meeting, April 26 to May 3, 2014, in Philadelphia, PA. The poster (4009), is titled, "Safety and Efficacy Study of...
Apr 23, 2014 General Releases HTML PDF
EMERYVILLE, Calif., April 15, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Adamas) (Nasdaq:ADMS), a specialty pharmaceutical company, today announced the closing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share. The shares began trading on The NASDAQ Global Market under the ...
Apr 15, 2014 General Releases HTML PDF
Emeryville, Calif., April 9, 2014 – Adamas Pharmaceuticals, Inc. (Adamas), a specialty pharmaceutical company, today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. The shares are expected to begin tradin...
New York, NY and Emeryville, CA - March 04, 2014 - Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, and Adamas Pharmaceuticals Inc., a privately held specialty pharmaceutical company, announced Forest's submission of a New Drug Application (NDA) to th...
Mar 4, 2014 General Releases HTML PDF
EMERYVILLE, CA, January 9, 2014 - Adamas Pharmaceuticals, Inc. announced today that it has received $40 million in milestone payments from Forest Laboratories Holdings Limited (NYSE: FRX) for MDX-8704. MDX-8704 is a fixed dosed combination (FDC) of Namenda XR® (memantine HCl extended release capsules) and donepezil HCl being developed as a ...
Jan 9, 2014 General Releases HTML PDF
Montreal, Canada and Emeryville, CA, October 02, 2013 - Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED™ clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development for the treatment of levodopa-induced ...
Oct 2, 2013 General Releases HTML PDF
Emeryville, Calif., June 18, 2013 - Adamas Pharmaceuticals, Inc. presented final results today from a Phase 2/3 clinical trial of ADS-5102 (amantadine HCl ER) capsules demonstrating a statistically significant improvement in levodopa-induced dyskinesia (LID) as measured by change from baseline at week 8 versus placebo in the Unified Dyskinesia R...
Jun 18, 2013 General Releases HTML PDF
Emeryville, Calif., June 10, 2013 - Adamas Pharmaceuticals, Inc. announced today that the Company’s Phase 2/3 EASED™ (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia) clinical trial of ADS-5102 (Nurelin™; amantadine HCl extended release) met the study's primary endpoint. ADS-5102 is an inves...
Jun 10, 2013 General Releases HTML PDF
Emeryville, Calif., April 22, 2013 - Adamas Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,389,578 entitled "Composition and method for treatment of neurological disease." The claims of this invention are directed towards improved methods for treating Parkinson's disease ...
Apr 22, 2013 General Releases HTML PDF
Emeryville, Calif., March 20, 2013 - Adamas Pharmaceuticals, Inc. will present research results today from its Nurelin™ (amantadine HCl extended release capsules) program demonstrating the benefit of amantadine in traumatic brain injury (TBI) at the 65th American Academy of Neurology (AAN) Annual Meeting being held in San Diego, CA. Nureli...
Mar 20, 2013 General Releases HTML PDF
NEW YORK & EMERYVILLE, CA, November 13, 2012 - Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical company, and Adamas Pharmaceuticals, Inc. announced today that they have entered into an agreement for the development and commercialization of a fixed dosed combination (FDC) of Namenda XR® (memantine HCl extended relea...
Nov 13, 2012 General Releases HTML PDF
EMERYVILLE, CALIF., June 4, 2012 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its NurelinTM (amantadine HCl extended release capsules) program at the Cambridge Healthtech Institute’s (CHI) Targeting Parkinson’s Disease Symposium being held today in Philadelphia. Nurelin, ...
Jun 4, 2012 General Releases HTML PDF
EMERYVILLE, CALIF., May 15, 2012 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has held an End-of-Phase 2 meeting with the FDA to discuss the proposed safety and efficacy studies to be conducted for the registration of Arimenda (memantine HCl extended release and donepezil HCl) capsules. Arimenda, a once-daily...
May 15, 2012 General Releases HTML PDF
EMERYVILLE, CALIF., September 28, 2011 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease. Called E...
Sep 28, 2011 General Releases HTML PDF